Germacrane Sesquiterpenoids
as a New Type of Anticardiac
Fibrosis Agent Targeting Transforming Growth Factor β Type I
Receptor
Version 2 2019-08-26, 12:33
Version 1 2019-08-23, 20:15
Posted on 2019-08-26 - 12:33
A germacrane sesquiterpenoid library
containing 30 compounds (2–31) was
constructed by structural modification
of a major component aristolactone (1) from the traditional
Chinese medicine Aristolochia yunnanensis. Compound 11 was identified as a promising anticardiac
fibrosis agent by systematic screening of this library. 11 could inhibit the expression of fibronectin (FN), α-smooth
muscle actin (α-SMA), and collagens in transforming growth factor
β 1 (TGFβ1)-stimulated cardiac fibroblasts at a micromolar
level and ameliorate myocardial fibrosis and heart function in abdominal
aortic constriction (AAC) rats at 5 mg/kg dose. Mechanistic study
revealed that 11 inhibited the TGFβ/small mother
against decapentaplegic (Smad) signaling pathway by targeting TGFβ
type I receptor (IC50 = 14.9 ± 1.6 nM). The structure–activity
relationships (SARs) study indicated that the unsaturated γ-lactone
ring and oxidation of C-1 were important to the activity. These findings
may provide a new type of structural motif for future anticardiac
fibrosis drug development.
CITE THIS COLLECTION
DataCite
3 Biotech
3D Printing in Medicine
3D Research
3D-Printed Materials and Systems
4OR
AAPG Bulletin
AAPS Open
AAPS PharmSciTech
Abhandlungen aus dem Mathematischen Seminar der Universität Hamburg
ABI Technik (German)
Academic Medicine
Academic Pediatrics
Academic Psychiatry
Academic Questions
Academy of Management Discoveries
Academy of Management Journal
Academy of Management Learning and Education
Academy of Management Perspectives
Academy of Management Proceedings
Academy of Management Review
Lou, Lan-Lan; Ni, Fu-Qiang; Chen, Lin; Shaker, Sharpkate; Li, Wei; Wang, Rong; et al. (2019). Germacrane Sesquiterpenoids
as a New Type of Anticardiac
Fibrosis Agent Targeting Transforming Growth Factor β Type I
Receptor. ACS Publications. Collection. https://doi.org/10.1021/acs.jmedchem.9b00708
or
Select your citation style and then place your mouse over the citation text to select it.
SHARE
Usage metrics
Read the peer-reviewed publication
AUTHORS (8)
LL
Lan-Lan Lou
FN
Fu-Qiang Ni
LC
Lin Chen
SS
Sharpkate Shaker
WL
Wei Li
RW
Rong Wang
GT
Gui-Hua Tang
SY
Sheng Yin
KEYWORDS
Compound 11Anticardiac Fibrosis Agent Targeting Transforming Growth Factor β Typecomponent aristolactoneChinese medicine Aristolochia yunnanensisIC 50germacrane sesquiterpenoid library30 compoundsSMAGermacrane SesquiterpenoidsTGF β typeγ- lactone ringaortic constrictionFNNew TypeSARmicromolar levelheart functionAACanticardiac fibrosis agentgrowth factor β 1Mechanistic studyfuture anticardiac fibrosis drug development